Actionable news
All posts from Actionable news
Actionable news in REGN: Regeneron Pharmaceuticals, Inc.,

Analysts Weigh In on Three Healthcare Giants: Gilead Sciences, Inc. (GILD), Regeneron Pharmaceuticals Inc (REGN), Abbott Laboratories (ABT)


Analysts are weighing in on pharmaceutical giants Gilead Sciences, Inc. (NASDA:GILD), Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and Abbott Laboratories (NYSE:ABT) with mixed ratings. The analysts reflect on Gilead’s recent FDA approval, Regeneron’s Sarilumab prospects, and Abbott’s risk/reward.

Gilead Sciences, Inc.

Gilead announced yesterday evening that the FDA has approved Harvoni (ledipasvir/sofosbuvir) for expanded use in patients with genotype 4, 5, and 6 chronic hepatitis C virus (HCV) infection and in patients co-infected with HIV. In addition, Harvoni plus ribavirin (RBV) for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment-experienced, genotype 1 patients with cirrhosis.

Maxim analyst Jason Kolber commented, “Gilead continues to be the leader in our biotechnology universe. It has a consistent base (HIV), with HCV driving growth. The company continues to develop its “other” franchises as HCV outshines. We see upside as Japan starts to build. Harvoni now stands to eliminate genotype testing.”

Kolbert rates Gilead Sciences a Buy, with a price target of $137, which represents a potential upside of 34% from where the stock is currently trading.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of -12.9% and a 28% success rate. Kolbert has a 15.7% average return when recommending GILD, and is ranked #3834 out of 3842...